Dasatinib as Salvage Therapy for Steroid Refractory and Imatinib Resistant or Intolerant Sclerotic Chronic Graft-Versus-Host Disease

Biology of Blood and Marrow Transplantation - Netherlands
doi 10.1016/j.bbmt.2011.10.042
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Imatinib Mesylate for the Treatment of Steroid-Refractory Sclerotic-Type Cutaneous Chronic Graft-Versus-Host Disease

Biology of Blood and Marrow Transplantation
TransplantationHematology
2015English

Cost-Effectiveness of Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Phase Chronic Myeloid Leukemia

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

Tocilizumab for Steroid Refractory Acute Graft-Versus-Host Disease

Leukemia and Lymphoma
Cancer ResearchOncologyHematology
2015English

Late Onset and Protracted Course of Steroid Refractory Chronic Graft-Versus-Host Disease

Case Reports in Hematology
2015English

Combination of Bortezomib Plus Ruxolitinib in Steroid-Refractory Chronic Graft-Versus-Host Disease

Bone Marrow Transplantation
TransplantationHematology
2018English

Response to Thalidomide Therapy in Refractory Chronic Graft-Versus-Host Disease

Bone Marrow Transplantation
TransplantationHematology
2000English

Sirolimus for Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease

Bone Marrow Transplantation
TransplantationHematology
2009English

Phase II Pilot Study of Imatinib Mesylate for the Treatment of Severe Sclerotic Skin Chronic Graft Versus Host Disease (ScGVHD)

Biology of Blood and Marrow Transplantation
TransplantationHematology
2012English

Rituximab Provides Steroid-Sparing Therapy in New-Onset Chronic Graft-Versus-Host Disease

Biology of Blood and Marrow Transplantation
TransplantationHematology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy